Clinical Trial Update: Multiple Antigen-Engineered DC Vaccine for Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating a multiple antigen-engineered dendritic cell vaccine for melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Snippet

Sponsor: Lisa H. Butterfield, Ph.D. | Conditions: Melanoma | Phase 1 | Status: COMPLETED